Changes are coming to our lives and world that may rival the industrial and internet revolutions. Jeremy Schwartz and Kara Marciscano discuss the BioRevolution already underway and identify the range of business sectors we believe are best positioned to benefit.
We believe that there is an opportunity in the current quality market that should not be overlooked. Jeremy Schwartz explains how investors can seek to take advantage of this opportunity.
If Chinese stocks cannot get their act together, the unwanted “October surprise” could be a rerating of U.S. equity valuations in response to now-reduced peer valuations. Against this backdrop, Jeff Weniger outlines two potential options for investors to investigate.
Many investors have behavioral biases that may cause them to be under-exposed to quality in their portfolios. Matt Wagner makes the case for tilting toward quality in today’s market environment.
We believe 2021 may mark a turning point for international equity markets. Brian Manby explains why investors should consider focusing on the quality factor when investing abroad.
There is potential for interest rates to rise in reaction to or in anticipation of a red-hot Q2 GDP report. Jeff Weniger outlines small-cap strategies to potentially get ahead of it.
We believe value and dividend payers still have room to run following historical outperformance to start the year. Against this backdrop, Matt Wagner explains why investors should consider allocating toward higher-quality dividend payers.
